{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-222750","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2026-05-14T11:05:16+00:00","discovered_at":"2026-05-14T11:10:00.299239+00:00","generated_at":"2026-05-14T11:12:01.068854+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"EyePoint receives third positive DSMC recommendation for Phase 3 wet AMD DURAVYU trials","bullets":["DSMC recommends LUGANO and LUCIA continue without modification; all active treatment-arm patients have received second DURAVYU dose.","Over 35% of patients have received third planned dose at Week 56; safety profile consistent with >190 patients across prior trials.","Topline data from LUGANO expected mid-2026; LUCIA readout to follow shortly after.","Trials enroll over 900 patients; primary endpoint is non-inferiority in mean BCVA change at weeks 52 and 56."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-222750","json":"https://secwatch.observer/filing/0001193125-26-222750.json","markdown":"https://secwatch.observer/filing/0001193125-26-222750.md","text":"https://secwatch.observer/filing/0001193125-26-222750.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526222750/0001193125-26-222750-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526222750/eypt-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T11:12:01.068854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}